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THE PROTECTIVE ROLE OF FAT SPECIFIC PROTEIN 27 (FSP27) AGAINST 
INTERLEUKIN-1 BETA AND INTERLEUKIN-6 INDUCED LIPOLYSIS AND 
INSULIN RESISTANCE IN HUMAN ADIPOCYTES 
MELISSA CAITLIN DELIO 
ABSTRACT 
 The global rise in the prevalence of obesity has been labeled a pandemic. The 
increasing rates of overweight and obese persons across the world is discerning, as 
obesity is a risk factor for many life-threatening and debilitating diseases including type 
two diabetes mellitus (T2DM), a disease that decreases insulin sensitivity of skeletal 
muscle, adipose tissue and liver, and insulin secretion in pancreatic beta cells. Despite its 
pervasiveness, the mechanism by which obesity causes T2DM remains elusive. Adipose 
tissue is known to contribute to whole body glucose metabolism and as a result has been 
implicated in T2DM. Obesity causes changes in the physiology of adipose tissue, 
including hypertrophy of adipocytes, rendering them stressed and dysfunctional. The 
result is an increase in free fatty acids in the blood, due to increased lipolysis and 
decreased triglyceride storage. Free fatty acids have been shown to cause insulin 
resistance in insulin sensitive tissues. It has also been observed that in some patients, 
obesity results in inflammation of adipose tissue. As adipocytes enlarge, they not only 
secrete increasing amounts of free fatty acids, they also secrete chemoattractant proteins 
like MCP-1, which attract macrophages. These macrophages secrete inflammatory 
cytokines such as Tumor Necrosis Factor- alpha, Interleukin-1beta and Interleukin-6, 
among others, which have been shown to alter adipose tissue metabolism by increasing 
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lipolysis and decreasing triglyceride storage. In addition, inflammatory cytokines have 
been suspected to play a role in insulin resistance, although the exact mechanisms remain 
elusive.  
The present study explored the possibility that IL-1β and IL-6 affect insulin 
signaling in human adipocytes by increasing lipolysis, thus increasing free fatty acids in 
the blood. Recent studies have emphasized the role of fat specific protein 27 (FSP27) in 
the regulation of lipolysis in adipocytes whereby, FSP27 controls lipolysis by regulating 
the lipolytic capacity as well as transcription of the primary lipase ATGL. In the present 
study we used FSP27 as a tool to investigate if managing lipolysis could protect human 
adipocytes from the impairment of insulin signaling caused by the presence of 
inflammatory cytokines. 
We found that IL-1β and IL-6 increase lipolysis in human adipocytes by 
depression of endogenous FSP27 protein levels and that the rate of lipolysis can be 
rescued by adenoviral expression of FSP27. In addition, we found that IL-1β decreased 
insulin signaling by decreasing phosphorylation of AKT and that adenoviral expression 
of FSP27 has a protective effect over IL-1β - induced impairment of insulin signaling in 
human adipocytes. Our experiments regarding the effect of IL-6 on insulin signaling were 
inconclusive and need further experimentation. These results suggest that the 
inflammatory cytokine IL-1β indirectly suppresses insulin signaling, by increasing 
lipolysis and that maintenance of FSP27 protein levels in obese patients could prevent 
patients from developing insulin resistance and T2DM. 
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INTRODUCTION 
The increased prevalence of overweight and obese persons (individuals with a 
body mass index (BMI) of 30 kg/m2 or greater) worldwide has been labeled a pandemic1 . 
Between 1980 and 2013, the global occurrence of overweight and obesity combined 
increased by 27.5% for adults and 47.1% for children1. Along with an increased 
incidence of obesity, comes an increased threat of a plethora of diseases including 
cardiovascular diseases, type 2 diabetes mellitus (T2DM) and certain forms of cancer, 
making effective treatment for this disease imperative2. Not only would a cure for obesity 
decrease mortality rates, it would also be economically beneficial to society as well, as 
obesity can result in many debilitating and costly disorders including osteoarthritis, 
benign prostate hypertrophy, infertility, asthma, and sleep apnea2. Of all the pathologies 
associated with obesity, T2DM is the most prevalent metabolic disease in the world3. 
Despite its pervasiveness, the link between obesity and T2DM remains poorly 
understood3.  
Not all individuals that are obese develop T2DM; however, all obese persons that 
develop T2DM share two physiological pathologies. One, the insulin sensitive tissues, 
adipose tissue, liver and skeletal muscle, become unresponsive to insulin and two, their 
pancreatic β-cells secrete insufficient levels of insulin to maintain normal fasting glucose 
levels4,5. The pathway by which obesity leads to both pathologies is poorly understood, 
however, recent research has shown that adipose tissue is involved in the regulation of 
whole-body glucose homeostasis4. This suggests that in obese individuals, the 
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metabolism of adipose tissue is altered which results in primary insulin resistance in 
insulin sensitive tissues and T2DM4. 
 
Adipose Tissue Metabolism and Function 
Energy metabolism in mammals is problematic in the sense that energy utilization 
is constant while energy intake is periodic6. As a result, mammals must be able to store 
energy and mobilize it quickly if necessary6. As a solution to this problem, mammals 
utilize the circulatory system, which transports fuel to all cells, as well as, liver and 
adipose tissue, which store and exchange substrates with the blood6. Adipose tissue, 
specifically white adipose tissue, is the chief location of energy storage from a positive 
energy balance6. White adipose tissue is made up of cells called white adipocytes which 
store predominantly fatty acids and to a lesser extent, glucose in the form of triglycerides 
(TGs)6. Glucose must be transformed into fatty acids by a process called lipogenesis 
before it is esterified with internal glycerol to form triglyceride; however, in human 
adipose tissue, lipogenesis only accounts for a small percentage of lipid storage6. The 
main source of fatty acids comes from triglycerides carried in the blood via very low 
density lipoproteins (VLDL) formed in the liver and chylomicrons produced in the 
intestine6. Within the adipocyte, these TGs are stored in a solitary, large lipid droplet 
surrounded by an assortment of proteins, which control the storage and breakdown of 
fat4.  
During food deprivation, lipolysis takes place and TGs are broken down by 
lipases into three fatty acids and glycerol and released into the blood4. Three lipases 
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responsible for the breakdown of TGs are: Adipose Triglyceride Lipase (ATGL), 
Hormone Sensitive Lipase (HSL) and Monoacylglycerol Lipase (MGL)6.  ATGL is the 
rate-limiting enzyme in adipocytes, as it catalyzes the first step of lipolysis turning TG to 
diacylglycerol and fatty acid7. ATGL must interact with comparative gene identification-
58 (CGI-58), a coactivator protein in order to reach it’s full lipolytic ability8. In the basal 
state, this protein associates with lipid droplet protein perlipin-1 (PLIN-1) preventing it 
from binding to ATGL and thus preventing lipolysis8. When β-adrenergic receptors are 
activated, protein kinase A (PKA) becomes activated, and phosphorylates PLIN-1, 
releasing CGI-58 which can then bind to and stimulate ATGL, increasing lipolysis8. 
These fatty acids that are liberated from adipocytes, are absorbed by peripheral tissues 
where they react with coenzyme A to form long-chain acyl-CoA (metabolically active), 
moderating their noxiousness4. Eventually, during fasting or exercise the fatty acids are 
oxidized in the mitochondria for energy9.  
In addition to it’s energy storage capabilities, adipose tissue also has an endocrine 
role, as it secretes numerous hormones and cytokines which can act in an autocrine 
manner or a paracrine manner, affecting distant tissues like liver, brain and muscle4. 
These molecules contribute to whole body metabolism and may have neuroendocrine 
control over behaviors related to feeding4. 
 
Adipose Tissue Dysfunction Leads to Insulin Resistance 
Obesity alters fat metabolism causing insulin resistance. Although it is vital that 
mammals have the ability to mobilize fatty acids in a time of need, an excess of fatty 
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acids in the blood can be pathological, leading to a disruption of biological membranes, 
cellular PH and generation of dangerous bioactive lipids8. The result can be 
mitochondrial dysfunction, inflammation, endoplasmic reticulum stress and even cell 
death, all of which are symptoms of lipotoxicity8. 
 It has been shown that in rodents and humans, high fat diets can alter fat 
metabolism in adipose tissue4. When calorie intake balances energy output, adipocytes 
remain normal in size allowing them to maintain a level of fatty acids in the blood that 
can be oxidized by the enzymes of the mitochondria of insulin sensitive tissues, causing 
low fatty acyl-CoA levels within these tissues. This allows these tissues to remain insulin 
sensitive and to continue with normal glucose uptake4. However, in obesity, adipocytes 
increase in size as more TGs are deposited4. To compensate for the influx of fatty acids, 
the activity of the enzymes involved in the formation of TGs also increases to maintain 
the normal rate of lipolysis4. Although fatty acid levels in the blood may rise, the insulin 
sensitive tissues remain insulin sensitive4. Eventually, plasma free fatty acid levels rise in 
obese individuals because the enlarged and stressed adipose tissue releases more free 
fatty acids and free fatty acid clearance is decreased10. 
 
Free fatty acids induce insulin resistance. Elevated plasma free fatty acids are one 
of the factors responsible for insulin resistance10. The insulin receptor (InsR), is a dimeric 
transmembrane protein with tyrosine kinase activity11. Normally, when insulin binds the 
receptor, substrate proteins (IRS-1) bind to the intracellular portion of the receptor and 
become phosphorylated and activated11. These proteins activate phosphatidylinositol-3-
 5 
kinase (PI3K) which phosphorylates and activates v-akt murine thymoma viral oncogene 
(AKT) leading to glucose transporter 4 (GLUT-4) mobilization11. GLUT-4 is mobilized 
from cellular vesicles to the cell membrane where it mediates transport of glucose from 
the blood into the cell5.   
Free fatty acids have inhibitory effects on early steps in the insulin signaling 
pathway, such as phosphorylation and inhibition of IRS proteins through activation of 
Ser/Thr kinases, Jun N-terminal kinase (JNK), mammalian target of rapamycin complex-
1 (mTORC1), protein kinase Cθ (PKCθ), IKKβ and p70 ribosomal S6 kinase (p70S6K)4 
(Figure 1). Elevated fatty acids cause an accumulation of intracellular fat metabolites, 
including fatty acyl-CoA and diacylglycerol, which trigger protein kinase C (PKC). 
Active, PKC phosphorylates IRS proteins, inhibiting insulin signaling in the skeletal 
muscle of rodents4.  
According to Boden, a physiological link between obesity and insulin resistance, 
must meet three criteria: the factor must be increased in the blood of obese people, 
elevation in the blood should increase insulin resistance, and lowering of levels in the 
blood should decrease insulin resistance10. Currently, in humans only free fatty acids 
meet all three of these criteria; however, there may be other biological molecules released 
by adipose tissue which could mediate the progression of obesity to T2DM10. 
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Figure 1: Free Fatty Acids Induce Insulin Resistance. Free fatty acids which enter the 
cells of the peripheral tissues, are either stored in the form of triglycerides or oxidized in 
the mitochondria for energy. When there is a mass influx of free fatty acids, the enzymes 
that control these pathways become overwhelmed and as a result fatty acid intermediates 
like diaclyglycerol, ceramide and linoleic acid are increased. These intermediates activate 
PCKθ, which becomes phosphorylated. PCKθ activates down stream targets, JNK and 
IKK which associate with IRS-1, promoting serine312 phosphorylation in humans and 
serine307 phosphorylation in rodents. This serine phosphorylation inhibits IRS-1, 
preventing it from interacting with the insulin receptor, causing insulin resistance5.    
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Dysfunction of adipose tissue leads to inflammation. It has recently been 
suggested that inflammatory cytokines, Tumor Necrosis Factor-alpha (TNF- α), 
Interleukin-1 beta (IL-1β) and Interleukin-6 (IL-6), as well as Monocyte chemoattractant 
protein-1 (MCP-1), may play a role in the mechanism by which free fatty acids lead to 
insulin resistance10. As adipocytes enlarge, as seen in obesity, not only is their ability to 
store triglycerides affected, but also their ability to secrete biologically active proteins 
called adipokines4. Adipokines potentially mediate fat metabolism dynamics, as they are 
positively correlated with insulin resistance, in most cases, independently of the degree of 
obesity3,4. 
As adipocytes increase in size they produce increasing amounts of MCP-1, a 
potent chemoattractant of macrophages4. In addition, endothelial cells have also been 
shown to secrete MCP-1 in response to cytokines5. MCP-1 has been shown to increase 
the macrophage content to as high as 50% of the total number of adipose tissue cells in 
obese individuals4 (Figure 2). These macrophages can have one of two phenotypes: the 
“classically activated macrophages” phenotype (M1), which secrete pro-inflammatory 
cytokines such as IL-1β, IL-6, TNF- α, or the “alternatively activated macrophages” 
phenotype (M2) which produce anti-inflammatory cytokines interleukin-10 (IL-10)3. 
Obesity has been shown to provoke a phenotypic switch from the M2 to M1 phenotype, 
correlating with insulin resistance both in mice and humans3.  It seems that an increased 
content of M1 macrophages can impair insulin signaling and adipogenesis in adipocytes 
whereas M2 macrophages seem to protect against obesity-induced insulin resistance3. 
The signals from M1 macrophages create a pro-inflammatory environment which may 
 8 
lead to insulin resistance4. The exact mechanism by which these pro-inflammatory 
cytokines lead to insulin resistance remains to be determined; however, it has been shown 
that these cytokines affect adipocyte function by increasing lipolysis and decreasing TG 
synthesis4. 
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Figure 2: The Progression Of Obesity To Insulin Resistance In Skeletal Muscle. A In 
normal adipose tissue there is a balance between fatty acid storage and release. 
Adipocytes remain normal in size and skeletal muscle remains insulin sensitive. B If 
there is excessive calorie intake, there is an influx of fatty acids, and adipocytes enlarge 
in size to maintain the normal level of fatty acid in the blood. Skeletal muscle may 
remain sensitive. C As adipocytes continue to increase in size, they can no longer 
maintain fatty acid balance. Adipocytes hypertrophy and start secreting chemoattractant 
proteins like MCP-1, which causes an infiltration of macrophages. D Macrophages create 
a pro-inflammatory environment as they secrete many pro-inflammatory cytokines, 
including TNF-α. These cytokines impair the deposition of triglycerides and increase 
lipolysis, increasing the amount of free fatty acids in the blood. Excess free fatty acids in 
the blood, result in an increase in activated lipids in skeletal muscle that leads to insulin 
resistance 4. 
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Adipose tissue inflammation mediates insulin resistance. Adipose tissue 
inflammation mediates insulin resistance both directly and indirectly11. Cytokines may 
exacerbate the negative actions of excessive circulating free fatty acids on insulin 
signaling, by increasing lipolysis in adipocytes or they may act directly on the insulin 
signaling pathway in skeletal muscle, adipose tissue and liver. All of the steps of the 
insulin signaling pathway (discussed previously) are potential targets of adipose tissue 
derived inflammatory molecules in insulin sensitive tissues11. 
 
Mediators of Inflammation in Insulin Resistance and T2DM 
 TNF-α is a versatile cytokine secreted predominantly by the adipocytes of adipose 
tissue, which is involved in inflammatory processes, apoptosis, production of cytokines 
and insulin resistance12. TNF-α has been suspected of being the link between obesity and 
T2DM because protein and mRNA levels are elevated in the adipose tissue of mice and 
humans13,14. Much research has been devoted to the study of TNF- α induced insulin 
resistance. It is known that TNF-α affects insulin signaling both directly and indirectly 12. 
Previous studies have shown that TNF-α directly inhibits insulin-stimulated 
phosphorylation of the insulin receptor and IRS-1 through activation of IKK-β12. In 
addition TNF-α suppresses insulin signaling through other mechanisms such as down 
regulation of IRS-1, GLUT-4, Peroxisome Proliferator-Activated Receptors-gamma 
(PPAR-γ), CCAAT/enhancer-binding protein alpha (CEBP-α), PLIN-1 and adipocyte 
complement-related protein of 30 kDa (Acrp30) protein expression12.  
 11 
In addition, TNF-α indirectly induces insulin resistance by increasing lipolysis 
and increasing free fatty acids12. It has been suggested that TNF-alpha acts via activation 
of NF-kB, to inhibit key adipogenic genes, leading to lipolysis and insulin resistance12. 
Although much is known about TNF-α, there are other inflammatory cytokines whose 
targets and actions remain poorly understood. 
IL-1β is an inflammatory cytokine produced by macrophages and has been 
implicated in T2DM3. IL-1β is produced when a macrophage receives two physiological 
signals (Figure 3). The first signal is a pro-inflammatory signal that stimulates the 
transcription of IL-1β and storage of the inactive form of the cytokine, pro- IL-1β3. The 
second signal induces cleavage of pro- IL-1β by caspase-1 and thus production of the 
active hormone. Caspase-1 is activated by a large cytoplasmic multiprotein complex 
called the NLRP3 inflammasome3. It is poorly understood what triggers the production of 
IL-1β, but it has been suggested that the inflammasome may be sensitive to many of the 
signals that accumulate during obesity, for example, high levels of glucose, saturated free 
fatty acids, and lipid intermediates such as ceramides and uric acid3.  In addition, the 
level of NLRP3 inflammasome, IL-1β and the enzymatic activity of caspase-1 are all 
elevated in adipose tissue, mainly in macrophages, of obese mice and humans3. These 
changes indicate the level of insulin resistance, suggesting that IL-1β may play a role3.  
 Previous studies have shown that IL-1β has direct effects on the insulin-signaling 
pathway. It has been shown that administering a very high concentration of IL-1β in 
murine adipocytes decreases IRS-1 and GLUT-4 protein, whereas chronic treatment 
decreased IRS-1 and AKT phosphorylation15-17. However, IL-1β may have indirect 
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affects on the insulin-signaling pathway, as previous studies have shown that IL-1β 
induces lipolysis in murine and human adipocytes18-20.  As previously mentioned, excess 
free fatty acids induce insulin resistance. In addition Gao et al. found that IL-1β produced 
by macrophages affects insulin signaling and pro-inflammatory responses in human 
adipocytes by increasing cytokine production and lipolysis while decreasing glucose 
consumption21. This paracrine loop between macrophages and adipocytes involving fatty 
acids and cytokines creates a vicious cycle which could maintain the inflammatory status 
of adipose tissue and lead to insulin resistance; however, the exact mechanism by which 
IL-1β causes lipolysis thus insulin resistance remains elusive22.  
 It has been suggested that the Map kinase and IKK/nuclear factor (NF)-kB 
pathways, which frequently act in conjunction to facilitate cytokine action, may be 
involved23. Jager et al. recently found that Tpl2, a mitogen-activated protein kinase 
kinase kinase (MAP3K8) triggered by inflammatory provocations such as TNF-α, IL-1β 
and Lipopolysaccharides, in adipocytes, induces lipolysis and IRS-1 serine 
phosphorylation through ERK activation23. Similarly, Ceppo et al. found that Tpl2, 
mainly in macrophages is involved in the molecular communication between adipocytes 
and macrophages that promotes an inflammatory environment and may disrupt insulin 
signaling in adipocytes22. However, the role of Tpl2 in IL-1β mediated insulin resistance 
remains controversial in the literature, and there are multiple pathways besides the ERK 
pathway which may be involved22.  
 13 
 
 
 
Figure 3: The Production Of IL-1β. IL-1β is produced by macrophages, which contain a 
multi protein complex called the NLRP3 inflammasome. The inflammasome has three 
components: NLRP3, an adaptor protein ASC, and pro-caspase 1, which when activated 
will become caspase-1. Once activated, caspase-1 cleaves pro- IL-1β into its active form, 
IL-1β. NLRP3 becomes activated by two signals. The first signal acts on Toll-like 
receptors or cytokine receptors and activates the NFKB pathway, which leads to 
transcription of NLRP3 and pro-IL-1β. The second signal is an activating signal, which 
leads to NLRP3 inflammasome formation and caspase-1 activation3. 
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IL-6 is a multi-functional cytokine, released from immune cells during 
inflammatory conditions, as well as adipose tissue and skeletal muscle in non-
inflammatory conditions24,25. The IL-6 receptor is a part of the cytokine class I receptor 
family which involves the JAK/STATS (Janus kinases/signal transducers and activators 
of transcription) signaling pathway26.  Once activated, Janus kinase induces 
phosphorylation of STAT, dimerization and translocation to the nucleus where it 
regulates transcription26 Most of the IL-6 produced in adipose tissue comes from the 
stroma including preadipocytes, endothelial cells and monocytes, compared to the mature 
adipocytes26.  
The level of IL-6 has been shown to be a gauge for the risk of T2DM after 
adjustment of extraneous factors 27. In addition, previous studies show that IL-6 directly 
induces insulin resistance in mice by a declination of transcription and protein expression 
of GLUT-4, IRS-1 and Peroxisome Proliferator-Activated Receptor gamma (PPARγ), as 
well as a reduction in glucose absorption in murine adipocytes28.  
Similarly, plasma concentrations of Interleukin-6 and free fatty acids are elevated 
in patients with T2DM which suggests that interleukin-6 may induce lipolysis and thus 
insulin resistance9,29. Previous studies have shown that IL-6 increases lipolysis in 
humans; however, there is disagreement in the literature about its site of action. For 
example, Hall et al. found that infusion of IL-6 in humans increased lipolysis without 
causing hypertriacylglycerolemia in human subjects25. Similarly, Path et al. found that 
IL-6 stimulated glycerol release in human breast adipocytes30. However, while Wolsk et 
al. found that infusion of rhIL-6 in humans potentiated lipolysis of skeletal muscle, 
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adipose tissue lipolysis was unaffected24. More research is needed to determine if IL-6 
does in fact cause lipolysis in human adipose tissue.  
In addition, the mechanism by which IL-6 causes lipolysis and thus insulin 
resistance has yet to be determined; however, in 2008 Yang et al. found that a long-term 
high concentration of IL-6 administered to porcine adipocytes intensified lipolysis by 
activating ERK, which decreased perilipin A, promoting expression of Peroxisome 
Proliferator-Activated Receptor Gamma Coactivator 1-alpha (PGC-1α)9. It is not clear 
whether the same mechanism induces lipolysis in humans.  
Conversely, Zhang et al. suggested another mechanism by which lipolysis 
increases production of IL-6, that leads to insulin resistance in humans. It is known that 
stimulation of β3-adrenergic receptors (ADRB3) induces lipolysis and production of IL-6 
in adipocytes in a hormone sensitive lipase manner (HSL)31. Zhang et al. found that 
stimulation of these receptors up-regulates sphingosine kinase 1(SPHK1) and increases 
sphingosine-1-phosphate (S1P), a versatile serum borne bioactive lipid mediator, 
production in adipocytes in a manner that depends on HSL activity31. This suggests that 
Sphk1 is a mediator of lipolysis initiated IL-6 production31. It still remains to be 
determined whether IL-6 causes lipolysis, increasing fatty acids, which lead to insulin 
resistance, or if lipolysis increases IL-6 production, which directly affects insulin 
signaling. Perhaps it is a combination of both.  
 
Fat Specific Protein 27 (FSP27) Regulates Lipolysis 
 
There are numerous lipid droplet proteins that are involved in the dynamics 
between TG storage and breakdown. Recently a protein, Fat Specific Protein 27 (FSP27) 
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has been discovered which increases the size of lipid droplets4. FSP27 is part of a family 
of proteins called cell-death-inducing DFF45-like effectors (CIDEs) which share an 
amino acid sequence similar to the N-terminal domains in DFF45 (a 45 kDa inhibitor), as 
well as in DFF40 (a 40kDa caspase-activated nuclease)32. At first it was believed that 
there was no human homologue to FSP27, however, in 2003 this hypothesis changed 
with the discovery of CIDE-C33. Currently, three human CIDE proteins have been 
classified (CIDE-A, CIDE-B and CIDE-C) and three murine CIDE proteins (CIDE-A, 
CIDE-B, FSP27)34. FSP27 shares the same CIDE-C and CIDE-N domains as its fellow 
CIDE proteins and is capable of apoptosis. In addition to it’s apoptotic function, the 
distribution of FSP27 which is highly expressed in adipose tissue suggested another role 
for FSP2735.  
Puri et al. found that FSP27 is specifically localized in the lipid droplets of 
adipocytes and associates with PLIN1, a known lipid droplet protein (Figure 4)35. It was 
also discovered that depletion of endogenous FSP27 in mature adipocytes increased 
lipolysis, reducing the size of lipid droplets, suggesting that this lipid droplet protein 
promotes TG accumulation35. In addition, a homozygous nonsense mutation in FSP27 
has been associated with lipodystrophy in white adipose tissue while ablation or down 
regulation decreases lipid droplet size which has been linked to partial lipodystrophy in 
adipocytes 36 37.  Specifically, FSP27 impedes lipolysis and stimulates TG storage by 
interacting and inhibiting ATGL7. At the transcriptional level, FSP27 has been shown to 
suppress the activity of the ATGL promoter in vitro, through proximal interaction with 
the early growth response transcription factor (Egr1), binding site38.  Additionally FSP27 
 17 
has been shown to have an effect on insulin action as depletion of FSP27 in human 
adipocytes increases lipolysis and inhibits insulin signaling by reducing AKT 
phosphorylation7. 
In patients with the same BMI, it has been shown that the extent of mRNA 
expression of lipid droplet proteins, is related to insulin resistance4. This suggests that 
lipid droplet proteins like FSP27 may play a role in lipolysis mediated insulin resistance, 
by decreasing lipolysis and promoting TG storage4. In fact, decreased FSP27 may be a 
result of down regulation of this protein by inflammatory cytokines leading to increased 
lipolysis and free fatty acids4. This suggests that if we could regulate FSP27, we could 
control cytokine induced lipolysis and insulin resistance. This hypothesis is supported by 
previously published studies. Ranjit et al. found that FSP27 has a protective effect over 
TNF-α induced lipolysis in murine adipocytes18. Whether the same is true in human 
adipocytes remains to be determined.  
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Figure 4: FSP27 Regulation Of Lipolysis. This is a hypothetical model proposed for the 
mechanism by which FSP27 regulates lipolysis. PLIN1 anchors FSP27 on the surface of 
the lipid droplet where FSP27 interacts with ATGL to decrease lipolysis. A During basal 
conditions, FSP27 prevents ATGL from binding to coactivator CGI-58, decreasing 
lipolysis. B In the absence of FSP27 under basal conditions, ATGL binds CGI-58, 
increasing lipolysis. C Following β-adrenergic stimulation in the presence of FSP27, 
PKA becomes activated and phosphorylates PLIN1 and hormone sensitive lipase, 
releasing CGI-58, which binds to and stimulates ATGL. Unbound ATGL in translocated 
to lipid droplets, and G0S2 (an inhibitor of ATGL) is down regulated increasing ATGL-
mediated lipolysis. D Upon β-adrenergic stimulation in the absence of FSP27, the 
otherwise FSP27 sequestered ATGL is available for CGI-58 binding resulting in even 
higher levels of lipolysis7.  
 
7 
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Specific Aims of Current Study 
Although the effect of IL-1β and IL-6 on lipolysis has been studied in murine and 
porcine adipocytes, as well as in vivo human studies, limited studies have been 
performed on human adipocytes. The present project studied: 
1. If the inflammatory cytokines IL-1β and IL-6 induce lipolysis and impair insulin 
signaling in human adipocytes (Figure 5).  
2. If administering FSP27 to human adipocytes protected the cells from cytokine 
mediated lipolysis and impaired insulin signaling.  
Overall, these studies indicated that pro-inflammatory cytokine IL-1β increases lipolysis 
and impairs insulin signaling in human adipocytes. These effects on lipolysis and insulin 
signaling are protected by FSP27 overexpression. In addition the present study indicated 
that IL-6 increases lipolysis in human adipocytes. While the present study indicates that 
the effects of IL-6 on lipolysis in human adipocytes can be protected by FSP27 
overexpression, our results regarding the effect of IL-6 on insulin signaling were 
inconclusive and need further experimentation. This research has therapeutic value and 
could potentially lead to treatment of obesity and T2DM.  
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Figure 5: Does FSP27 Have A Protective Role Against IL-1β and IL-6 Induced 
Lipolysis And Insulin Resistance? This study will examine if inflammatory cytokines, 
IL-1β and IL-6 induce lipolysis by decreasing endogenous FSP27 in human adipocytes. 
In addition we will examine if IL-1β and IL-6 have a negative effect on insulin signaling. 
Finally, we will explore whether maintaining a constant level of FSP27 will have a 
protective effect against IL-1β and IL-6 mediated lipolysis and insulin resistance.   
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METHODS 
 
Culture and Differentiation of Human Pre-Adipocytes Into Adipocytes 
Human pre-adipocytes were provided by the Boston Nutrition Obesity Research 
Center adipocyte core. 5,000 cells/ml/well were seeded in a 12-well plate, and were given 
MEM Growth Medium (Gibco) supplemented with 10% FBS (Gibco), 100 units/ml of 
penicillin and streptomycin (Gibco) and 25 mM Sodium Bicarbonate (Fishcer Scientific) 
pH 7.2-7.3. Every 2 days the growth medium was replaced with fresh media, until cells 
reached 90% confluence. Once the cells reached 90% confluence the growth medium was 
then replaced by complete Differentiation Medium, which consisted of: 13.5 g of 
Dulbecco’s Modified Eagle’s medium powder (DMEM/F12) (Gibco), 100 units/ml of 
penicillin and streptomycin (Gibco, 15 mM Hepes (Sigma), 25 mM Sodium Bicarbonate 
(Fischer Scientific), 33 µM Biotin (Sigma), 17µM pantothenate (Sigma), 0.5 mM IBMX 
(Sigma), 10mg/L Transferrin (Sigma), 1 µM Rosiglitazone (BioMol), 100 ηM 
Dexamethasone (Sigma), 100 ηM Human Insulin (recombinant), 2 ηM triiodo-l-
thyronine (T3) (sigma), reconstituted in ddH2O to 1 liter, PH 7.4. The day cells were first 
given Complete Differentiation Media was considered as Day 0. Every 2 days the 
differentiation media was replaced until the preadipocytes differentiated into mature 
human white adipocytes, recognizable by visible white lipid droplets. Following 
differentiation, the cells were maintained in maintenance media until fully differentiated 
with the media being made of: 13.5 g of Dulbecco’s Modified Eagle’s medium powder 
(DMEM/F12) (Gibco), 25 mM Sodium Bicarbonate (Fischer Scientific), 100 units/ml of 
penicillin and streptomycin (Gibco), 25 mM Hepes (Sigma), 33 µM d-Biotin (Sigma), 17 
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µM pantothenate (Sigma), 10 ηM Dexamethasone (Sigma), 10 µM Human Insulin 
(recombinant), reconstituted in ddH2O to 1 liter, PH 7.4. 
 
Adenoviral Transduction of Human Adipocytes 
FSP27-CFP virus (75 µl/well) was added to differentiated adipocytes containing 
500 µl of maintenance media on day 9 of differentiation. 3-4 hours following infection, 
500 µl of maintenance media was added to each well. The media was changed 48 hours 
post infection, on the day the cells were treated. Cells were harvested 24 hours later for 
analysis.  
 
IL-1β and IL-6 Challenge 
In order to evaluate IL-1β-mediated lipolysis and it’s effect on endogenous FSP27 
protein levels in human adipocytes, differentiated adipocytes were incubated with 
maintenance media with or without 1 ηg/ml rhIL-1β (R&D Systems) for 24 hours at 
37°C.  
In order to evaluate IL-6 mediated lipolysis and it’s effect on endogenous FSP27 
protein in human adipocytes, differentiated adipocytes were incubated with maintenance 
media with or without 3 ηg/ml rhIL-6 (R&D Systems) for 24 hours at 37°C.  
 In order to evaluate the protective effect of FSP27 on IL-1β and IL-6 mediated 
lipolysis, appropriate wells were treated with FSP27-CFP adenovirus on day 9 of 
differentiation. Cells were assessed for CFP expression 48 hours post infection. After 48 
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hours, the media was changed with normal media or media containing 1 ηg/ml rhIL-1β or 
3 ηg/ml rhIL-6. Cells were incubated for 24 hours at 37°C.  
 
Measurement of Lipolysis 
The extent of lipolysis was measured by the amount of glycerol released in 400 µl  
Krebs-Ringer buffer (24.6 mM NaHCO3, 1.11 mM KH2PO4, 130 mM NaCl, 4.7 mM 
KCL, 1.24 mM MgSO4, 3.3 mM CaCl2, 4% w/v BSA, 5 mM Glucose pH 7.4) incubated 
with cells with the appropriate concentration of rhIL-6 (3 ηg/ml) or rhIL-1β (1 ηg/ml), for 
2 hours. Then the buffer was collected and analyzed for glycerol release under basal 
conditions. 12.5 µl KRB or consecutive dilutions of glycerol standard solution were 
combined with 50 µl of free glycerol reagent (Sigma) and incubated at 37°C for 15 
minutes. Absorbance was quantified by a spectrophotometer (Bio-Rad) set to a 
wavelength of 540 ηm. Using the glycerol standards, a standard curve was generated, 
which was used to calculate the concentration of glycerol in each sample. 
 
Insulin Signaling In Human Adipocytes  
In order to evaluate the effect of IL-1β or IL-6 on insulin signaling, differentiated 
adipocytes were given normal media or media containing 1 ηg/ml rhIL-1β or 3 ηg/ml 
rhIL-6 and were incubated for 24 hours at 37°C. After 24 hours the media was collected 
and the cells were washed with phosphate buffered saline (PBS) three times. Then Krebs 
Ringer HEPES (KRH) buffer with 5mM glucose was added with or without 1 ηg/ml IL-
1β or 3 ηg/ml IL-6 for serum starvation. After 2.5 hours at 37°C, the KRH was aspirated 
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off and the cells were washed with PBS three times. After, KRH without glucose 
containing no cytokine as a control, rhIL-1β (1 ηg/ml) or rhIL-6 (3 ηg/ml) , with or 
without insulin (10 ηm) was added. Cells were incubated for 15 minutes at 37°C. After 
15 minutes, cells were washed twice with PBS and harvested for analysis of AKT 
phosphorylation as a measure for insulin signaling. Phosphorylated AKT was normalized 
to total AKT.   
In order to evaluate the protective effect of FSP27 on IL-1β and IL-6 mediated 
insulin resistance, the appropriate wells were treated with FSP27-CFP adenovirus on day 
9 of differentiation. Cells were assessed for CFP expression 48 hours post infection. At 
48 hours, differentiated adipocytes were incubated with maintenance media as a control 
or media containing 1 ηg/ml rhIL-1β or 3 ηg/ml rhIL-6 for 24 hours at 37°C and AKT 
phosphorylation was measured as described above.  
 
Protein Analysis 
Total intracellular protein was measured in 100 µl cell lysis buffer (Cell 
Signaling) containing 5% SDS, protease inhibitor cocktail (Roche) and phosphatase 
inhibitor cocktail (Roche). Protein lysates were then briefly sonicated, and then 
centrifuged at 10,000 rpm for 10 minutes. The clear middle phase of the solution was 
then collected as the protein sample. Protein quantification was performed using the 
Pierce BSA Protein Assay Kit (Thermo Scientific). 5 µl cell lysis buffer or consecutive 
dilutions of BSA (Sigma) were combined with 95 µl of protein reagent and incubated for 
30 minutes at 37°C. The absorbance was quantified by a spectrophotometer (Bio-Rad) set 
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to a wavelength of 562 ηm. A protein standard curve was generated using the absorbance 
of the standard solutions, and the protein concentration of each sample was calculated 
using the curve. Immunoblots were performed using 10-12% Tris-HCL gels (Bio-Rad), 
run at 90 volts for 120 minutes, and transferred to PVDF membranes (Bio-Rad), run at 50 
volts for 120 minutes. Primary antibodies used were all diluted in 2% BSA in TBS-T. 
Antibodies used were mouse anti-Phospho-AKT(Invitrogen 1:1000 dilution), rabbit anti-
AKT (Invitrogen 1:1000 dilution), mouse anti-CIDEC (Invitrogen 1:3000 dilution), and 
mouse anti-β-actin (Invitrogen 1:4000). Secondary antibodies were purchased from Santa 
Cruz Biotechnology (1:5000 dilution).  
 
Statistical Analysis 
Quantitative data are portrayed as a mean ± standard deviation. Statistical 
significance was calculated using a paired student’s t-test. A p-value of ≤ 0.05 was 
considered statistically significant.  
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RESULTS 
IL-1β and IL-6 increase lipolysis in human adipocytes. 
With limited studies on IL-1β induced lipolysis in human adipocytes, we sought 
to further study the topic. First, the lowest concentration and time interval was 
determined for optimal lipolysis by treating human adipocytes with various 
concentrations of IL-1β (1 ηg/ml, 2 ηg/ml and 5 ηg/ml) for different time periods (8 
hours, 24 hours and 48 hours) and measuring rates of glycerol release (Figure 6). We 
obtained this range of doses and time courses from previously published studies21. The 
greatest rate of lipolysis was achieved when adipocytes were treated with a concentration 
1 ηg/ml for 24 hours. Since, similar rates of lipolysis were observed when the cells were 
treated for 24 hours versus 48 hours, we decided to use the shorter time interval of 24 
hours for our study. Under these conditions, there was a 1.6 fold increase in glycerol 
release. It is possible that the rate of lipolysis was underestimated in the cells treated with 
2 ηg/ml and 5 ηg/ml IL-1β for 48 hours either due to toxicity or experimental error.  
After the ideal concentration and time course was established, we explored if IL-
1β consistently increased lipolysis in human adipocytes. We found that 24-hour treatment 
with 1 ηg/ml rhIL-1β significantly increased glycerol release from human adipocytes 
(Figure 7A). There was a 1.57 ± 0.41 fold change in glycerol release under these 
conditions (p ≤ .05).  
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Figure 6: IL-1β Time Course and Dose Dependency Of Lipolysis In Human 
Adipocytes. Differentiated Adipocytes were treated with 0, 1, 2 or 5 ηg/ml IL-1β for 8, 
24 or 48 hours. The degree of lipolysis was assessed by measuring ηg of glycerol per µg 
of protein. Treatment with 1 ηg/ml IL-1β for 24 hours induced the greatest rate of 
lipolysis in human adipocytes. Glycerol release increased 1.6 fold under these conditions, 
when compared to the control. Image is representative of one experiment performed 
once. 
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A  
B  
Figure 7: Adenoviral Expression Of FSP27 Protects Against IL-1β - Induced 
Lipolysis. Human Adipocytes were infected with FSP27-CFP on day nine. On day 
eleven, cells were given maintence media with or without 1 ηg/ml IL-1β and analyzed for 
protein and glycerol released. A ηg glycerol released into KRB + 4% BSA per µg protein. 
Image is representative of at least three experiments. All values are means ± SD. * = p ≤ 
.05  B Adipocytes Showing CFP expression (Green) in human adipocytes expressing 
FSP27-CFP in the absence of cytokine.  
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Previous studies have examined IL-6 mediated lipolysis in live human subjects, 
human breast adipocytes, murine adipocytes and porcine adipocytes; however, there are 
inconsistencies in the literature regarding the effect of IL-6 on human adipocytes and 
murine adipocytes. For example, Wolsk et al. found that while IL-6 increased lipolysis in 
skeletal muscle, there was no effect of IL-6 on human adipose tissue24. Similarly, Ranjit 
et al. found that IL-6 did not increase glycerol release in murine adipocytes18. 
Conversely, Path et al. found that IL-6 increased lipolysis in human breast adipocytes30. 
We hoped to clarify these inconsistencies in the literature. We did so first by determining 
the lowest concentration and time interval for optimal lipolysis by treating human 
adipocytes with various concentrations of IL-6 (1 ηg/ml, 3 ηg/ml and 6 ηg/ml) for 
different time periods (8 hours, 24 hours and 48 hours) and measuring rates of glycerol 
release (Figure 8). We observed similar rates of lipolysis for all three time intervals; 
however, we found that the greatest rate of lipolysis with the smallest time interval was 
achieved when adipocytes were treated with 3 ηg/ml IL-6 for 24 hours. We obtained this 
range of doses and time courses from previously published studies30. Under these 
conditions, there was a 1.8 fold increase in glycerol release. It is possible that the rate of 
glycerol release for the cells treated with 3 ng/ml and 6 ng/ml IL-6 for 48 hours is an 
underestimation possibly due to toxicity or experimental error. Similar to IL-1β, in 
human adipocytes we sought to investigate whether IL-6 consistently prompted lipolysis. 
As shown in figure 9A, administering 3 ηg/ml rhIL-6 for 24 hours significantly increased 
glycerol release from human adipocytes. Under these conditions there was a 1.35 ± 0.18 
fold increase in glycerol release (p ≤ .05).  
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Figure 8: IL-6 Time Course and Dose Dependency Of Lipolysis In Human 
Adipocytes. Differentiated Adipocytes were treated with 0, 1, 3 or 6 ηg/ml IL-6 for 8, 24 
or 48 hours. The degree of lipolysis was assessed by measuring ηg of glycerol per µg of 
protein. The greatest rate of lipolysis in the shortest amount of time was observed when 
adipocytes were treated with 3 ηg/ml rhIL-6 for 24 hours. Under these conditions there 
was a 1.8 fold increase in glycerol release compared to the control. Image is 
representative of one experiment performed once.  
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Figure 9: Adenoviral Expression Of FSP27 Protects Against IL-6 - Induced 
Lipolysis. Human Adipocytes were infected with FSP27-CFP on day nine. On day 
eleven, cells were given maintence media with or without 3 ηg/ml IL-6  for 24 hours and 
analyzed for protein and glycerol released. A ηg glycerol released into KRB + 4% BSA 
per µg protein. Image is representative of at least three experiements. All values are 
means ± SD. * = p ≤ .05 B Adipocytes Showing CFP expression (Green) in human 
adipocytes expressing FSP27-CFP in the absence of cytokine.  
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IL-1β and IL-6 decrease endogenous FSP27 levels in human adipocytes. 
 
Since IL-1β has been shown to induce lipolysis in human adipocytes, and that 
FSP27 has been shown to decrease lipolysis, we hypothesized that an increase in IL-1β 
would deplete endogenous FSP27, leading to an increase in lipolysis. Previous studies 
using murine adipocytes have shown that IL-1β decreases FSP27 levels, we sought to test 
if the same holds true in human adipocytes 18.  In order to determine if IL-1β has an effect 
on FSP27 levels, we determined if adipocytes treated with a concentration of IL-1β that 
stimulated lipolysis, also down regulated endogenous FSP27 protein levels. Western 
blotting was used to analyze FSP27 protein expression after which we found that 
treatment with 1 ηg/ml IL-1β for 24 hours decreased FSP27 protein levels by ~ 23% 
(Figure 10). This suggests that IL-1β may induce lipolysis by decreasing FSP27 protein.  
We tested the same hypothesis on IL-6, since we found that IL-6 did in fact 
increase lipolysis in human adipocytes. Although it has been shown that in murine 
adipocytes treated with IL-6, there was no affect on FSP27 levels, we wanted to see if the 
same were true in human adipocytes18. After differentiated adipocytes were treated with 
IL-6, western blotting was used to analyze protein expression of FSP27. We found that 
adipocytes treated with 3 ηg/ml IL-6 for 24 hours decreased endogenous protein levels of 
FSP27 by ~ 16% after 24 hours (Figure 10). This suggests that in human adipocytes, IL-6 
induces lipolysis via suppression of FSP27 protein. 
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Figure 10: IL-1β and IL-6 Deplete Endogenous Levels of FSP27 Protein in Human 
Adipocytes. A. Western blotting was used to assess FSP27 protein expression using 
FSP27 and β-actin antibodies. FSP27 protein levels were normalized to β-actin used as a 
loading control. Treatment for 24 hours with 1 ηg/ml IL-1β caused a decrease in the 
FSP27 protein level by ~ 23%. Treatment for 24 hours with 3 ηg/ml IL-6 caused a 
decrease in FSP27 protein expression by ~ 16%. Image is based on one experiment 
performed in duplicate.  
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Expression of adenoviral FSP27 protects against IL-1β and IL-6- induced lipolysis. 
  To confirm if FSP27 is involved in the mechanism by which IL-1β induced 
lipolysis, we maintained the level of FSP27 in the presence of IL-1β by administering a 
FSP27 adenovirus. Plain maintenance media or maintenance media containing adenoviral 
FSP27-CFP was added to adipocytes 48 hours before treatment. 48 hours later cells were 
monitored for fluorescence and then treated with maintenance media with or without 1 
ηg/ml IL-1β for 24 hours. There was a 0.70 ± 0.20 fold decrease in lipolysis in cells 
infected with FSP27 adenovirus compared to the control (p ≤ .05) suggesting that FSP27 
decreases lipolysis. In addition, there was a 0.83 ± 0.05 fold decrease in glycerol release 
in the cells infected with FSP27 virus and treated with 1 ηg/ml IL-1β for 24 hours 
compared to the control (p ≤ .05) (Figure 7A). This is a significant decrease in lipolysis 
compared to the cells treated with IL-1β only (Figure 7A) (p ≤ .05). This result suggests 
that a constant level of FSP27 significantly prevents the increase in lipolysis normally 
seen in the presence of IL-1β.  
We also wanted to test the same hypothesis using IL-6 to see if FSP27 is involved 
in the mechanism by which IL-6 induced lipolysis. To test if IL-6 induces lipolysis by 
depressing FSP27 protein levels, we maintained the level of FSP27 in the presence of IL-
6 by administering a FSP27 adenovirus to see whether high FSP27 expression could 
prevent lipolysis upon cytokine treatment. Control or maintenance media containing 
adenoviral FSP27-CFP was fed to differentiated human adipocytes. 48 hours later cells 
were monitored for fluorescence and were treated with maintenance media with or 
without 3 ηg/ml IL-6. There was a 0.76 ± 0.21 fold decrease in glycerol release in the 
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cells treated with FSP27 virus, compared to the control (p ≤ .05) suggesting that FSP27 
decreases lipolysis. (Figure 9A)  In addition, there was a 0.77 ± 0.04 fold decrease in 
lipolysis in cells infected with FSP27 adenovirus and treated with IL-6 compared to the 
control (p ≤ .05) (Figure 9A). This is a significant decrease in lipolysis compared to the 
cells treated with IL-1β only (Figure 9A) (p ≤ .05). The result was that a constant level of 
FSP27 significantly prevented the increase in lipolysis normally seen in the presence of 
IL-6 suggesting that FSP27 has a protective effect on IL-6 induced lipolysis.  
 
IL-1β impairs insulin signaling in human adipocytes. 
We analyzed the amount of serine312 phosphorylated AKT, an insulin signaling 
molecule, to test the effect of IL-1β on insulin signaling. Following 24-hour treatment 
with IL-1β we analyzed protein expression in human adipocytes using western blotting. 
IL-1β diminished insulin stimulated phosphorylation of Akt protein by ~ 59 % (Figure 
11A).  
 Following 24 hour treatment with IL-6 we analyzed protein expression of 
Phosphorylated-AKT. We determined that IL-6 increases insulin signaling by ~ 125 % 
(Figure 11B). These results are inconclusive as they are based on one experiment.  
 
FSP27 Is Protective Against Impaired Insulin Signaling In Cells Treated With IL-1β.   
 
 To test if regulation of FSP27 has a protective role in IL-1β induced impairment 
of insulin signaling, we maintained the level of FSP27 in the presence of IL-1β by 
administering a FSP27 adenovirus. Control (maintenance media) or FSP27-CFP 
adenovirus was added to differentiated adipocytes 48 hours before treatment. 48 hours 
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later cells were monitored for fluorescence and then treated with plain maintenance 
media as a control or maintenance media containing 1 ηg/ml IL-1β. Phospho-AKT 
protein levels were analyzed through western blotting as an indication of insulin 
signaling. There was a ~ 30% increase in phospho-AKT protein in the cells treated with 
FSP27 adenovirus and IL-1β compared to the cells just treated with IL-1β (Figure 11A). 
This result suggests that FSP27 has a protective role against IL-1β induced impairment of 
insulin signaling.  
We tested the same hypothesis using IL-6 to see if FSP27 is involved in the 
mechanism by which IL-6 suppresses insulin signaling. To test this hypothesis we 
maintained the level of FSP27 in the presence of IL-6 by administering a FSP27 
adenovirus (FSP27-CFP). Control or FSP27-CFP adenovirus was added to human 
adipocytes, 48 hours before treatment. 48 hours post infection the cells were monitored 
for fluorescence and cells were treated with plain maintenance media as a control or 
maintenance media containing 3 ηg/ml IL-6 for 24 hours. After 24 hours, the cells were 
harvested and Phospho-AKT protein was analyzed by western blotting as an indication of 
insulin signaling. Under these conditions we observed a ~ 26 % increase in phospho-
AKT protein in the cells treated with FSP27 and IL-6 compared to those just treated with 
IL-6  (Figure 11B). However, more experimentation is needed to confirm this result. 
These results are inconclusive. 
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Figure 11: The Effect of Adenoviral Expression Of FSP27 On Insulin Signaling In 
Adipocytes Treated With IL-1β and IL-6.Western blot analysis using phospho-AKT 
and Total AKT Antibodies. Phospho-AKT protein levels were normalized to total AKT 
as a loading control. A IL-1β western blot. TNF-α results are unpublished. Results are 
representative of two independent experiments. B IL-6 western blot. Results are based on 
one experiment performed once. 
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DISCUSSION 
In obese patients, adipose tissue metabolism is altered when adipocytes 
hypertrophy. As adipocytes increase in size, they increase their rate of lipolysis and 
decrease triglyceride storage resulting in an increasing amount of free fatty acids in the 
blood. It is known that free fatty acids cause insulin resistance in liver, muscle and 
adipose tissue, although recent evidence suggests that the beginning stages of insulin 
resistance occur in the adipose tissue and contribute to insulin resistance in the other 
insulin sensitive tissues39. In addition to an increase in free fatty acids, dysfunctional 
adipocytes also increase production of chemoattractants like MCP-1, which increase the 
infiltration of macrophages into adipose tissue. These macrophages increase the assembly 
of pro-inflammatory cytokines, like TNF-α, IL-1β, and IL-6. It has been shown that these 
cytokines affect adipose tissue biology; however, the biological mechanisms and 
mediators involved have yet to be isolated. Much research has been devoted to the effect 
of TNF-α on insulin resistance in human adipocytes; however, little is known about the 
effect of IL-1β and IL-6 on insulin resistance. In this project, we used human adipocytes 
to study the influence of IL-1β and IL-6 on lipolysis and insulin signaling.  
 The cytokine IL-1β has been shown to directly affect the insulin-signaling 
pathway through suppression of IRS-1, PI3K, p85α and GLUT-4 protein expression, as 
well as insulin-initiated phosphorylation of Akt21. However there is a possibility that IL-
1β indirectly causes insulin resistance by increasing lipolysis and fatty acids in the blood. 
Previous studies have shown that IL-1β has been shown to induce lipolysis in murine 
adipocytes and human adipocytes 18,21. In agreement with these studies we found that 
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administration of IL-1β increases the rate of glycerol release in cultured human 
adipocytes. We also found that IL-1β increases glycerol release in human adipocytes by a 
mechanism, which decreases endogenous FSP27 protein, a lipid droplet protein that has 
been shown to promote triglyceride storage. This finding is consistent with previous 
findings that in murine adipocytes, treatment with IL-1β decreases FSP27 protein 
expression 18. We also found that stabilization of endogenous levels of FSP27 by 
administration of FSP27 adenovirus protects the cells from IL-1β mediated lipolysis. 
  IL-6 may also mediate insulin resistance in humans as the level of IL-6 is 
positively correlated with the amount of body fat 17,27,40,41. In addition, IL-6 has been 
shown to be increased in the fat cells of insulin resistant patients 28. In 3T3-L1 
adipocytes, IL-6 directly suppresses insulin signaling by decreasing expression of the 
insulin signaling genes IRS-1, GLUT4 and PPARγ and reducing glucose uptake28. 
However, like IL-1β, IL-6 may indirectly affect insulin signaling by increasing lipolysis 
and increasing free fatty acids in the blood. There are inconsistencies in the literature 
regarding IL-6 mediated lipolysis in human adipocytes. For example, Hall et al. found 
that infusion of IL-6 in humans increased lipolysis and fat oxidation without causing 
hypertriacylglycerolemia in live human subjects 25. Similarly, Path et al. found that IL-6 
stimulated glycerol release in human breast adipocytes30. Conversely, while Wolsk et al. 
found that infusion of rhIL-6 in humans potentiated lipolysis of skeletal muscle, adipose 
tissue lipolysis was unaffected 24. We found that IL-6 did in fact induce lipolysis in 
human adipocytes. We also have found that IL-6 increases glycerol release in human 
adipocytes through a mechanism, which decreases endogenous FSP27 protein. 
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Additionally we found that stabilization of endogenous levels of FSP27 by administration 
of FSP27 adenovirus protects the cells from IL-6 induced lipolysis suggesting that FSP27 
is involved in the mechanism by which IL-6 induces lipolysis.  
Also in agreement with previous studies we found that administration of IL-1β 
suppresses insulin signaling by decreasing the level of phosphorylated AKT in human 
adipocytes. We also found that stabilization of endogenous levels of FSP27 by 
administration of FSP27 adenovirus had a protective effect on insulin signaling in human 
adipocytes treated with IL-1β. Our experiments on the effect of IL-6 on insulin signaling 
were inconclusive.  
 These results suggest that the cytokine, IL-1β indirectly mediates insulin 
resistance by increasing lipolysis and increasing harmful free fatty acids in the blood. The 
results of the present study also suggest that the deleterious effects of IL-1β on insulin 
signaling can be rescued by adenoviral expression of FSP27. Even though IL-6 has been 
shown to increase lipolysis, and FSP27 is protective over IL-6 mediated lipolysis, the role 
of IL-6 in insulin signaling still remains to be determined.  
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